Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00737737 · ClinicalTrials.gov registry record · Phase 4

Hormone Function in Men Treated for Pain With Opioids or Placebo

A Phase 4 study, sponsored by National Institute of Nursing Research (NINR).

Completed
Registry status
Phase 4
Development phase
8
Enrollment target

NCT00737737: Completed Phase 4 study, sponsored by National Institute of Nursing Research (NINR).

NCT00737737 is a Phase 4 study that has completed, run by National Institute of Nursing Research (NINR). The registered enrollment target is 8 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00737737, a Phase 4 study, has completed, sponsored by National Institute of Nursing Research (NINR).

COMPLETED
Registry status
Phase 4
Development phase
8 participants
Enrollment target

Study Summary

This study will examine hormone function in men with osteoarthritis pain and how it is affected by opioid medication (such as Percocet, Vicodin, MS Contin and morphine) versus placebo. Men between 30 and 65 years of age who have had moderate to severe osteoarthritis joint pain at least 5 days a week over the past 3 months may be eligible for this study. Candidates are screened with a physical examination, x-rays, laboratory and other tests, and questionnaires about pain, mood and medical health. They are given a pain diary to complete for 2 weeks. Participants are admitted to the hospital for two 12 hour overnight stays, during each of which they provide a 24-hour urine collection and have a small blood sample drawn every 20 minutes for 12 hours (from 8:00 p.m. to 8:00 a.m.) through a catheter that remains in place in a vein. Blood pressure and pulse are monitored during this time. After the catheter is removed, subjects complete questionnaires about their pain, mood and activity. For the several weeks between the two hospitalizations, subjects take either an opioid medication or placebo, or standard medication such as motrin and naprosyn, according to random assignment to one of the three groups. All participants will be allowed to take anti-inflammatory medications and acetaminophen during this time as needed, but no other pain medications or treatments. They are monitored two or three times a week by telephone and complete a pain diary. After the second hospitalization, subjects are tapered off the study medication. After 2 to 4 weeks of stopping medication, they return for a final outpatient visit to review pain or other medical problems and to have blood drawn.

Interventions

  • DRUG Placebo
  • DRUG MS Contin

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2008-08
Est. Completion 2014-04
Phase Phase 4

What the finished NCT00737737 record still lists

NCT00737737 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00737737 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00737737 about?

NCT00737737 is a clinical study titled "Hormone Function in Men Treated for Pain With Opioids or Placebo". This study will examine hormone function in men with osteoarthritis pain and how it is affected by opioid medication (such as Percocet, Vicodin, MS Contin and morphine) versus placebo. Men between 30 and 65 years of age who have had moderate to severe osteoarthritis joint pain at least 5 days a wee...

What is the current status of trial NCT00737737?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2008-08. Estimated completion is 2014-04.

What interventions are being tested in trial NCT00737737?

The interventions under investigation include: Placebo (DRUG), MS Contin (DRUG).

Who is sponsoring clinical trial NCT00737737?

This trial is sponsored by National Institute of Nursing Research (NINR), which has 46 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00737737's enrollment target sits among peer trials

8 1972nd of 2000 higher than 20 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00737737, the US trial registry maintained by the National Library of Medicine. NCT00737737 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.